Seattle-based Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced that Kyle Guse, CFO and General Counsel of Atossa Genetics will be a featured presenter at the 5th Annual Dawson James Small Cap Growth Conference on October 29, 2019, at 11:20 AM Eastern Time. The conference is being held at the Wyndham Grand Hotel in Jupiter, Florida.
Mr. Guse will provide an overview of the Company’s business model and growth strategy and will be available for one-on-one meetings. Interested investors may request a meeting time by contacting conference coordinator Karen Payne at email@example.com.
Recently, Atossa and The Dr. Susan Love Research Foundation announced that the Institutional Review Board (IRB) has approved a Phase 2 clinical study of Atossa’s intraductal microcatheter technology for the administration of fulvestrant in patients with early-stage breast cancer or ductal carcinoma in situ (DCIS). Susan Love, M.D., inventor of the technology, will advise Atossa as it conducts the trial. Atossa also entered into a clinical trial agreement with a major research university named in the 8k filing that Atossa filed on 10-14-2019 to conduct their Phase 2 clinical study of Atossa’s intraductal microcatheter technology for the administration of fulvestrant in patients with early-stage breast cancer or ductal carcinoma in situ (DCIS). Atossa Genetics is the owner of issued patents, pending patent applications, and medical device FDA 510(k) premarket notifications related to the treatment of breast conditions, including breast cancer and DCIS.
The Dr. Susan Love Foundation for Breast Cancer Research’s mission is to end breast cancer. It challenges the status quo to end breast cancer and improve the lives of people impacted by it now through education and advocacy. The Foundation drives collaborative, cutting-edge research with nontraditional partners, brings to light the collateral damage of treatment and seeks ways to diminish it, and interprets science to empower patients. Fast, flexible, and project-based, the Foundation actively engages the public in scientific research to ensure that it produces accurate and meaningful results. For the past 20 years, Dr. Love has dedicated her career to the eradication of breast cancer and pioneered some of the world’s more innovative research. From spearheading a partnership with NASA’s Jet Propulsion Laboratory to mapping the breast ductal system to harnessing the power of artificial intelligence to develop a handheld, self-reading ultrasound for breast cancer screening in underserved populations. For more information please visit https://drsusanloveresearch.org/
“While the origin of breast cancer is still not well understood, we do know a few things,” stated Dr. Love. “Each breast is comprised of six to 12 duct-lobule units that develop from one or a few stem cells at the time of puberty. In the vast majority of cases, when a woman gets breast cancer it is one and only one of those units; the rest of the breast is without disease. It was on the basis of this understanding that, years ago, I began to envision treatments that focused on the ‘sick duct’ only. Over the years a number of clinical trials have been conducted that demonstrate this approach leads to strong tumor treatment effects, because of the local delivery, and reduced systemic exposure, which hopefully produces fewer side effects. I am pleased that Atossa Genetics and a leading institution are carrying on the research I began and I look forward to advising on this important clinical trial.”
Post View Count : 1422